REGENXBIO Inc. (NASDAQ:RGNX) Q1 2023 Results Conference Call May 3, 2023 4:30 PM ET

Company Participants

Patrick Christmas - EVP and Chief Legal Officer

Ken Mills - CEO

Steve Pakola - Chief Medical Officer

Vit Vasista - CFO

Conference Call Participants

Gena Wang - Barclays

Dane Leone - Raymond James

Gospel Enyindah-Asonye - Morgan Stanley

Alec Stranahan - Bank of America

Ellie Merle - UBS

Lisa Walter - RBC Capital Markets

Caroline Palomeque - Berenberg Capital Markets

Operator

Good day, and thank you for standing by. Welcome to the REGENXBIO Inc. First Quarter 2023 Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Patrick Christmas, Executive Vice President and Chief Legal Officer. Please go ahead, sir.

Patrick Christmas

Good afternoon, and thank you for joining us today. Earlier this afternoon, REGENXBIO released financial and operating results for the first quarter ended March 31, 2023. The press release and data presentation are available on our website at www.regenxbio.com.

Today's conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend and other words of similar meaning.

Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the Risk Factors and the Management's Discussion and Analysis sections of REGENXBIO's annual report on Form 10-K for the full year ended December 31, 2022, and comparable Risk Factors section of REGENXBIO's quarterly reports on Form 10-Q, which are on file with the Securities and Exchange Commission and available on the SEC's website.

Any information we provide on this conference call is provided only as of the date of this call, May 3, 2023. And we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events or otherwise.

Please be advised that today's call is being recorded and webcast. In addition, any unaudited or pro forma financial information that may be provided is preliminary and does not purport to project financial positions or operating results of the company. Actual results may differ materially.

I would now like to turn the call over to Ken Mills, CEO of REGENXBIO. Ken?